BioWorld

Nov. 9, 2015

New HIV therapeutics benefit from two decades of research

The FDA approval of Gilead Sciences Inc.'s once-daily, single-tablet regimen branded Genvoya on its Nov. 5 PDUFA date adds another point on the development trajectory graph of antiviral therapies. (See BioWorld Today, Nov.6, 2015.) Read More

Most me-too drugs start before risk is abated

There can be only one first-in-class drug. Every drug developed after that is a me-too drug in the most basic sense. Read More

Week in review

Week in Washington

Word on the street

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

BioWorld Stock Index 2015

Nasdaq Stock Index 2015

Money raised by biotech: Jan. 1 - Nov. 5, 2015

Public financing of biotechnology companies: Commenced trading in October 2015

Public financing of biotechnology companies: Filed and pending IPOs

Other financings of public biotechnology companies: October 2015

2015 top financings of public companies

2015 top financings of private companies

Venture capital & other investments in private biotechnology companies: October 2015

Milestone payments from corporate partners: October 2015

Money raised by biotech in 2015 vs. 2014

Today's news in brief

BioWorld

BioWorld briefs for Feb. 9, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...